On September 11, 2020 Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin therapeutics, reported that Patrick Amstutz, chief executive officer, will be presenting at the HC Wainwright 22nd Annual Global Investments Conference taking place September 14-16, 2020, as well as participating in a fireside chat at the Morgan Stanley Global Healthcare Conference taking place September 14-18, 2020 (Press release, Molecular Partners, SEP 11, 2020, View Source(SIX%3A%20MOLN,Global%20Investments%20Conference%20taking%20place [SID1234565021]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentations are as follows:

HC Wainwright 22nd Annual Global Investments Conference

Presentation Date: Monday, September 14, 2020

Presentation Time: 11:30 a.m. ET

Morgan Stanley Global Healthcare Conference

Presentation Date: Wednesday, September 16, 2020

Presentation Time: 1:15 p.m. ET

A webcast of the presentations will be available on the Molecular Partners website.